Real-time PCR for monitoring minimal residual disease and chimerism in patients after allogeneic transplantation.

This publication has 8 references indexed in Scilit:

• Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state
  Blood, 2002
• The TEL‐AML1 real‐time quantitative polymerase chain reaction (PCR) might replace the antigen receptor‐based genomic PCR in clinical minimal residual disease studies in children with acute lymphoblastic leukaemia
  British Journal of Haematology, 2002
• Real‐time reverse transcription polymerase chain reaction detection and quantification of t(1;19) (E2A–PBX1) fusion genes associated with leukaemia
  British Journal of Haematology, 2001
• Pre-Clinical Validation of a Novel, Highly Sensitive Assay to Detect PML-RARα mRNA Using Real-Time Reverse-Transcription Polymerase Chain Reaction
  The Journal of Molecular Diagnostics, 2001
• Kinetics of BCR‐ABL fusion transcript levels in chronic myeloid leukemia patients treated with STI571 measured by quantitative real‐time polymerase chain reaction
  European Journal of Haematology, 2001
• Estimating the relapse stage in chronic myeloid leukaemia patients after allogeneic stem cell transplantation by the amount of BCR‐ABL fusion transcripts detected using a new real‐time polymerase chain reaction method
  British Journal of Haematology, 2001
• The AML1/MTG8 Fusion Transcript in t(8;21) Positive AML and its Implication for the Detection of Minimal Residual Disease; Malignancy.
  2001
• The AML1/MTG8 Fusion Transcript in t(8;21) Positive AML and its Implication for the Detection of Minimal Residual Disease
  Hematology, 2000